Dedicated view
After Conservative / Palliative Care
This view filters official records whose own descriptions refer to advanced, metastatic, recurrent or relapsed disease, later treatment lines, or supportive and palliative care. It exists for one reason: if you were told to consider conservative or palliative care and still want to see what official registries currently list, you can scan it here — calmly, in one place, and always via the original source.
Please read this first. A record appearing here does not mean it is suitable, available or appropriate for any individual. Inclusion is based only on wording in the official record — never on any judgement by this site. Discuss anything you find with your treating doctor.
Trial records retrieved live from the ClinicalTrials.gov public API.
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
ChiCTR — Chinese Clinical Trial Registry, public search
CTIS public register — search clinical trials authorised in the EU/EEA
ESMO Clinical Practice Guidelines — supportive and palliative care section
FDA — expanded access (compassionate use) information for patients
NCCN Guidelines — palliative care category listing
NCCN Guidelines for Patients — plain-language versions
药物临床试验登记与信息公示平台 — national registry of drug trials conducted in China
This site does not provide medical advice
TrialBeacon only aggregates links to publicly available official information. It does not recommend, rank or evaluate any treatment, trial or medicine, and nothing here implies suitability for any individual. Please discuss anything you find with your treating doctor, and always rely on the original official page — records change over time. Full disclaimer.
